Guj. Terce Labs.

Guj._Terce_Labs.29 Apr 2024

Pharmaceuticals

₹

+1.29 (+1.99%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Guj. Terce Labs.

Guj. Terce Labs.

Pharmaceuticals

Guj._Terce_Labs.29 Apr 2024

₹

+1.29 (+1.99%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
29-Mar-2024	BC	The Board at its meeting held today has approved the issue of fully convertible warrants on preferential basis Extraordinary General Meeting (EGM) of the shareholders of the company on Thursday, 2	25-Apr-2024
22-Mar-2024	BC	GUJARAT TERCE LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/03/2024 inter alia to consider and approve a proposal for raising of funds	29-Mar-2024
23-Jan-2024	BC	GUJARAT TERCE LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2024 inter alia to consider and approve Un-audited Financial Results fo	05-Feb-2024
31-Oct-2023	BC	GUJARAT TERCE LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve Un-audited Financial Results of	08-Nov-2023
07-Jun-2023	BC	Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Register of Members and Share Transfer Books of the Company will remain closed from Satu	25-Aug-2023

No Rights has been declared by Guj._Terce_Labs.

Book Closure

Record Date	Split Date	Purpose
25-Apr-2024	-	The Board at its meeting held today has approved the issue of fully convertible warrants on preferential basis Extraordinary General Meeting (EGM) of the shareholders of the company on Thursday, 2
29-Mar-2024	-	GUJARAT TERCE LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/03/2024 inter alia to consider and approve a proposal for raising of funds
05-Feb-2024	-	GUJARAT TERCE LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2024 inter alia to consider and approve Un-audited Financial Results fo
08-Nov-2023	-	GUJARAT TERCE LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve Un-audited Financial Results of
25-Aug-2023	-	Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Register of Members and Share Transfer Books of the Company will remain closed from Satu

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Gujarat Terce Laboratories Ltd ₹66.08(+1.29/1.99%)	66.08	+1.29	48.07	242.80	95.28	8.16
Astrazeneca Pharma India Ltd ₹5,556.10(+140.70/2.60%)	5,556.10	+140.70	13,538.50	71.09	84.88	20.67
Bliss GVS Pharma Ltd ₹124.45(+1.85/1.51%)	124.45	+1.85	1,283.51	60.79	18.80	1.31
Cipla Ltd ₹1,407.55(-1.85/-0.13%)	1,407.55	-1.85	113,794.25	54.54	34.60	4.40
Abbott India Ltd ₹26,277.60(+412.75/1.60%)	26,277.60	+412.75	54,962.81	15.87	47.98	17.68
Amrutanjan Health Care Ltd ₹709.40(+28.55/4.19%)	709.40	+28.55	1,968.38	13.21	44.73	7.51

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	13.02	12.03	10.72	12.89	11.90	12.58
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	13.02	12.03	10.72	12.89	11.90	12.58
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	0.08	0.08	0.08	0.10	0.08	0.10
Total Income	13.10	12.11	10.79	12.99	11.99	12.68
Total Expenditure	12.17	11.49	11.84	13.08	11.78	12.98
PBIDT	0.93	0.63	-1.05	-0.09	0.21	-0.30
Interest	0.16	0.20	0.17	0.17	0.14	0.22
PBDT	0.76	0.43	-1.22	-0.26	0.07	-0.52
Depreciation	0.09	0.09	0.09	0.16	0.07	0.07
Tax	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax	0.00	0.00	0.00	-1.22	0.00	0.00
Reported Profit After Tax	0.67	0.33	-1.31	0.80	0.00	-0.59
Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	0.67	0.33	-1.31	0.80	0.00	-0.59

EPS (Unit Curr.)	0.91	0.45	-1.76	1.08	0.00	-0.79
EPS (Adj) (Unit Curr.)	0.91	0.45	-1.76	1.08	0.00	-0.79
Calculated EPS (Unit Curr.)	0.91	0.45	-1.76	1.08	0.00	-0.79
Calculated EPS (Adj) (Unit Curr.)	0.91	0.45	-1.76	1.08	0.00	-0.79
Calculated EPS (Ann.) (Unit Curr.)	3.63	1.80	-7.05	4.33	-0.02	-3.17
Calculated EPS (Adj) (Ann.) (Unit Curr.)	3.63	1.80	-7.05	4.33	-0.02	-3.17
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	7.42	7.42	7.42	7.42	7.42	7.42
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	10.00	10.00	10.00	10.00	10.00	10.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	7.14	5.24	-9.79	-0.70	1.76	-2.38
PBDTM(%)	5.84	3.57	-11.38	-2.02	0.59	-4.13
PATM(%)	5.15	2.74	-12.22	6.21	0.00	-4.69

Column	Sep 21	Jun 21	Sep 20	Jun 20	Mar 20	Dec 19
Gross Sales	10.13	9.94	7.20	4.98	9.34	10.11
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	10.13	9.94	7.20	4.98	9.34	10.11
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	0.08	0.07	0.09	0.07	0.26	0.01
Total Income	10.20	10.01	7.28	5.05	9.61	10.12
Total Expenditure	9.59	8.31	7.09	5.38	9.84	9.66
PBIDT	0.61	1.70	0.19	-0.33	-0.24	0.47
Interest	0.10	0.05	0.17	0.05	0.10	0.04
PBDT	0.51	1.65	0.03	-0.38	-0.34	0.43
Depreciation	0.05	0.05	0.04	0.06	0.07	0.06
Minority Interest Before NP	0.00	0.00	0.00	0.00	0.00	0.00
Tax	0.00	0.00	0.00	0.00	0.21	0.00
Deferred Tax	0.00	0.00	0.00	0.00	-0.05	0.00
Reported Profit After Tax	0.45	1.60	-0.02	-0.44	-0.57	0.37
Minority Interest After NP	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit after Minority Interest	0.45	1.60	-0.02	-0.44	-0.57	0.37

Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	0.45	1.60	-0.02	-0.44	-0.57	0.37

EPS (Unit Curr.)	0.61	2.16	-0.02	-0.60	0.00	0.50
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	7.42	7.42	7.42	7.42	7.42	7.42

Public Shareholding (Number)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (%)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	6.02	17.10	2.64	-6.63	-2.57	4.65
PBDTM(%)	5.03	16.60	0.42	-7.63	-3.64	4.25
PATM(%)	4.44	16.10	-0.28	-8.84	-6.10	3.66

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	7.42	7.42	7.42	7.42	7.42	7.42
Reserves Total	-0.56	1.11	0.24	3.69	3.41	2.98
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	6.86	8.53	7.66	11.11	10.83	10.40
Secured Loans	6.41	6.04	4.54	2.57	0.65	0.34
Unsecured Loans	0.86	0.63	0.20	0.03	0.03	0.03
Total Debt	7.27	6.67	4.74	2.60	0.68	0.37
Total Liabilities	14.13	15.20	12.40	13.71	11.51	10.77
APPLICATION OF FUNDS :
Gross Block	8.33	8.28	6.16	6.10	10.78	9.99
Less : Accumulated Depreciation	4.35	3.99	3.71	3.80	8.72	8.12
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	3.98	4.29	2.45	2.30	2.06	1.87
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	0.00	0.00	0.00	0.00	0.00	0.00
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.27	0.27	0.27	0.27	0.29	0.27
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	4.43	6.43	3.74	3.43	3.78	3.79
Sundry Debtors	7.99	5.47	5.17	7.01	4.53	4.58
Cash and Bank	2.03	1.51	1.29	0.04	0.18	0.73
Loans and Advances	1.60	2.06	1.83	1.43	0.73	0.41
Total Current Assets	16.05	15.47	12.03	11.92	9.22	9.51
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	7.04	5.49	3.74	4.23	3.39	3.95
Provisions	3.75	3.35	3.65	2.61	2.73	2.95
Total Current Liabilities	10.79	8.84	7.40	6.85	6.11	6.91
Net Current Assets	5.25	6.63	4.63	5.07	3.10	2.61
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	1.72	0.47	0.42	0.16	0.30	0.05
Deferred Tax Liability	0.20	0.17	0.25	0.00	0.18	0.15
Net Deferred Tax	1.52	0.30	0.17	0.16	0.12	-0.10
Total Assets	11.03	11.49	7.52	7.79	5.57	4.66
Contingent Liabilities	0.00	0.00	0.00	0.00	0.00	0.00

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	1.51	1.29	0.04	0.18	0.73
Net Cash from Operating Activities	0.03	-0.44	-0.16	-1.59	-0.61
Net Cash Used In Investing Activities	0.62	-0.87	-0.42	-0.27	-0.13
Net Cash Used In Financing Activities	-0.12	1.53	1.83	1.72	0.20
Net Inc./Dec In Cash And Cash Equivalents	0.52	0.22	1.24	-0.14	-0.55
Cash And Cash Equivalents At End Of The Year	2.03	1.51	1.29	0.04	0.18

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

37.03%

FII Shareholding

0.00%

DII Shareholding

0.00%

Public Shareholding

62.97%

**Promoter pledged shareholding 37.03%

About Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 48.07 crores. It has reported a sales of Rs. 13.02 crores and a net profit of Rs. 0.67 crores for the quarter ended December 2018. The company management includes Natwarbhai P Prajapati, Amrutbhai P Prajapati,Chhayaben Ashwinbhai Shah,Viplav Suryakantbhai Khamar,Aalap Prajapati,Surendra Kumar Sharma,Navinchandra Patel,Natwarbhai P Prajapati (Gujarat Terce Laboratories Ltd) among others.

Chairman

Natwarbhai P Prajapati

Registered office

122/2 Ravi Estate,Bileshwarpura Chhatral,Gandhinagar,Gujarat,382729

FAX :

Background

Incorporation Year1985

Face Value₹10

Market Lot1

How to buy Guj. Terce Labs. shares on nse?

To buy Guj. Terce Labs. shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Guj. Terce Labs. share price today?

The Guj. Terce Labs. shares price on nse is Rs.66.08 today.

What is the market cap of Guj. Terce Labs. shares on BSE ?

The company has a market capitalization of Rs.48.07Cr

What is the PE & PB ratio of Guj. Terce Labs. shares ?

PE is 95.28 and PB is 8.16

What is the 52 Week High and Low of Guj. Terce Labs. shares?

Guj. Terce Labs. stock price high: Rs.70.91 Guj. Terce Labs. stock price low: Rs.16.65